Emerging Respiratory Viruses Section, Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD 20892-3203, United States.
Vaccine. 2012 Aug 17;30(38):5603-10. doi: 10.1016/j.vaccine.2012.06.088. Epub 2012 Jul 10.
We studied the replication of influenza A/California/07/09 (H1N1) wild type (CA09wt) virus in two non-human primate species and used one of these models to evaluate the immunogenicity and protective efficacy of a live attenuated cold-adapted vaccine, which contains the hemagglutinin and neuraminidase from the H1N1 wild type (wt) virus and six internal protein gene segments of the A/Ann Arbor/6/60 cold-adapted (ca) master donor virus. We infected African green monkeys (AGMs) and rhesus macaques with 2×10(6) TCID(50) of CA09wt and CA09ca influenza viruses. The virus CA09wt replicated in the upper respiratory tract of all animals but the titers in upper respiratory tract tissues of rhesus macaques were significant higher than in AGMs (mean peak titers 10(4.5) TCID(50)/g and 10(2.0) TCID(50)/g on days 4 and 2 post-infection, respectively; p<0.01). Virus replication was observed in the lungs of all rhesus macaques (10(2.0)-10(5.4) TCID(50)/g) whereas only 2 out of 4 AGMs had virus recovered from the lungs (10(2.5)-10(3.5) TCID(50)/g). The CA09ca vaccine virus was attenuated and highly restricted in replication in both AGMs and rhesus macaques. We evaluated the immunogenicity and protective efficacy of the CA09ca vaccine in rhesus macaques because CA09wt virus replicated more efficiently in this species. One or two doses of vaccine were administered intranasally and intratracheally to rhesus macaques. For the two-dose group, the vaccine was administered 4-weeks apart. Immunogenicity was assessed by measuring hemagglutination-inhibiting (HAI) antibodies in the serum and specific IgA antibodies to CA09wt virus in the nasal wash. One or two doses of the vaccine elicited a significant rise in HAI titers (range 40-320). Two doses of CA09ca elicited higher pH1N1-specific IgA titers than in the mock-immunized group (p<0.01). Vaccine efficacy was assessed by comparing titers of CA09wt challenge virus in the respiratory tract of mock-immunized and CA09ca vaccinated monkeys. Significantly lower virus titers were observed in the lungs of vaccinated animals than mock-immunized animals (p≤0.01). Our results demonstrate that AGMs and rhesus macaques support the replication of pandemic H1N1 influenza virus to different degrees and a cold-adapted pH1N1 vaccine elicits protective immunity against pH1N1 virus infection in rhesus macaques.
我们研究了甲型流感病毒/加利福尼亚/07/09(H1N1)野生型(CA09wt)病毒在两种非人类灵长类动物中的复制情况,并使用其中一种模型评估了一种活减毒冷适应疫苗的免疫原性和保护效力,该疫苗含有血凝素和神经氨酸酶来自 H1N1 野生型(wt)病毒和 A/Ann Arbor/6/60 冷适应(ca)主供体病毒的六个内部蛋白基因片段。我们用 2×10(6)TCID(50)CA09wt 和 CA09ca 流感病毒感染非洲绿猴(AGMs)和恒河猴。病毒 CA09wt 在所有动物的上呼吸道中复制,但恒河猴上呼吸道组织中的病毒滴度明显高于 AGMs(感染后第 4 天和第 2 天的平均峰值滴度分别为 10(4.5)TCID(50)/g 和 10(2.0)TCID(50)/g;p<0.01)。所有恒河猴的肺部都观察到病毒复制(10(2.0)-10(5.4)TCID(50)/g),而只有 4 只 AGMs 中有 2 只从肺部回收病毒(10(2.5)-10(3.5)TCID(50)/g)。CA09ca 疫苗病毒在 AGMs 和恒河猴中均减弱且复制受到高度限制。我们在恒河猴中评估了 CA09ca 疫苗的免疫原性和保护效力,因为 CA09wt 病毒在该物种中更有效地复制。通过鼻内和气管内途径向恒河猴施用一剂或两剂疫苗。对于两剂量组,疫苗间隔 4 周给药。通过测量血清中的血凝抑制(HAI)抗体和鼻洗液中针对 CA09wt 病毒的特异性 IgA 抗体来评估免疫原性。一剂或两剂疫苗可显著提高 HAI 滴度(范围 40-320)。两剂 CA09ca 引起的 pH1N1 特异性 IgA 滴度高于模拟免疫组(p<0.01)。通过比较模拟免疫和 CA09ca 接种猴子呼吸道中 CA09wt 挑战病毒的滴度来评估疫苗效力。接种动物的肺部病毒滴度明显低于模拟免疫动物(p≤0.01)。我们的结果表明,AGMs 和恒河猴对大流行性 H1N1 流感病毒的复制程度不同,冷适应 pH1N1 疫苗可在恒河猴中引发针对 pH1N1 病毒感染的保护性免疫。